Clinical Trial Update: A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on LOXO-305 (pirtobrutinib) in Chinese participants with B-cell malignancies, with results posted on July 16, 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• LOXO-305 (pirtobrutinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Leukemia, Lymphoid, Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED | Results posted: 2024-07-16